Drey Coleman

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

AMAG Pharma USA, Inc. engages in the provision of pharmaceutical products to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, government entities, and physicians. The company was founded by Victor M. Hermelin in 1942 and is headquartered in Waltham, MA.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.

Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ.

Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA.

Sirion Holdings, Inc. provides pharmaceutical products and medical devices for the ophthalmic market. It offers contract services, which includes clinical, regulatory, consulting, and medical education services. The company was founded by Susan K. Benton, Barry S. Butler, Philippe Boulangeat, and Vogel Roger in 2005 and is headquartered in Tampa, FL.

Mesa Verde Ventures LLC (Mesa Verde Ventures) is a venture capital firm founded in 2006. The firm is headquartered in San Diego, California.

RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI.

Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA.

Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA.

Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team.

Lifescan, Inc. engages in the development, manufacture, and market of blood glucose monitoring products. Its portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions. The company was founded by Gary H. Stroy in 1981 and is headquartered in Wayne, PA.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA.

Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA.

Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The company is based in Lexington, KY.

OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI.

Tarsier Pharma Ltd. operates as a research and development company focusing on development of drug candidates in the field of ophthalmology. It develops a novel treatment for uveitis based on technology inspired by biomimetics. The company was founded by Daphne Haim-Langford in February 2016 and is headquartered in Zichron Yaacov, Israel.

jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021.